156 related articles for article (PubMed ID: 30499025)
1. p110α and p110β isoforms of PI3K are involved in protection against H
Singh P; Bano N; Hossain MM; Basit R; Dar MJ
Breast Cancer; 2019 May; 26(3):378-385. PubMed ID: 30499025
[TBL] [Abstract][Full Text] [Related]
2. Dynamics of GFP-Fusion p110α and p110β Isoforms of PI3K Signaling Pathway in Normal and Cancer Cells.
Singh P; Dar MS; Singh G; Jamwal G; Sharma PR; Ahmad M; Dar MJ
J Cell Biochem; 2016 Dec; 117(12):2864-2874. PubMed ID: 27167447
[TBL] [Abstract][Full Text] [Related]
3. Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER
Hosford SR; Dillon LM; Bouley SJ; Rosati R; Yang W; Chen VS; Demidenko E; Morra RP; Miller TW
Clin Cancer Res; 2017 Jun; 23(11):2795-2805. PubMed ID: 27903677
[No Abstract] [Full Text] [Related]
4. p110α and p110β isoforms of PI3K signaling: are they two sides of the same coin?
Singh P; Dar MS; Dar MJ
FEBS Lett; 2016 Sep; 590(18):3071-82. PubMed ID: 27552098
[TBL] [Abstract][Full Text] [Related]
5. Nuclear but not cytosolic phosphoinositide 3-kinase beta has an essential function in cell survival.
Kumar A; Redondo-Muñoz J; Perez-García V; Cortes I; Chagoyen M; Carrera AC
Mol Cell Biol; 2011 May; 31(10):2122-33. PubMed ID: 21383062
[TBL] [Abstract][Full Text] [Related]
6. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
7. Both p110alpha and p110beta isoforms of phosphatidylinositol 3-OH-kinase are required for insulin signalling in the hypothalamus.
Tups A; Anderson GM; Rizwan M; Augustine RA; Chaussade C; Shepherd PR; Grattan DR
J Neuroendocrinol; 2010 Jun; 22(6):534-42. PubMed ID: 20236230
[TBL] [Abstract][Full Text] [Related]
8. Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.
Leroy C; Ramos P; Cornille K; Bonenfant D; Fritsch C; Voshol H; Bentires-Alj M
Breast Cancer Res; 2016 Apr; 18(1):41. PubMed ID: 27048245
[TBL] [Abstract][Full Text] [Related]
9. Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor.
Berenjeno IM; Guillermet-Guibert J; Pearce W; Gray A; Fleming S; Vanhaesebroeck B
Biochem J; 2012 Feb; 442(1):151-9. PubMed ID: 22150431
[TBL] [Abstract][Full Text] [Related]
10. Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.
Jeong JY; Kim KS; Moon JS; Song JA; Choi SH; Kim KI; Kim TH; An HJ
Apoptosis; 2013 Apr; 18(4):509-20. PubMed ID: 23371322
[TBL] [Abstract][Full Text] [Related]
11. Activity of any class IA PI3K isoform can sustain cell proliferation and survival.
Foukas LC; Berenjeno IM; Gray A; Khwaja A; Vanhaesebroeck B
Proc Natl Acad Sci U S A; 2010 Jun; 107(25):11381-6. PubMed ID: 20534549
[TBL] [Abstract][Full Text] [Related]
12. Enhanced Akt phosphorylation and myogenic differentiation in PI3K p110β-deficient myoblasts is mediated by PI3K p110α and mTORC2.
Matheny RW; Lynch CM; Leandry LA
Growth Factors; 2012 Dec; 30(6):367-84. PubMed ID: 23137199
[TBL] [Abstract][Full Text] [Related]
13. Class IA Phosphatidylinositol 3-Kinase Isoform p110α Mediates Vascular Remodeling.
Vantler M; Jesus J; Leppänen O; Scherner M; Berghausen EM; Mustafov L; Chen X; Kramer T; Zierden M; Gerhardt M; Ten Freyhaus H; Blaschke F; Sterner-Kock A; Baldus S; Zhao JJ; Rosenkranz S
Arterioscler Thromb Vasc Biol; 2015 Jun; 35(6):1434-44. PubMed ID: 25908763
[TBL] [Abstract][Full Text] [Related]
14. The Phosphoinosotide 3-Kinase Catalytic Subunit p110α is Required for Normal Lens Growth.
Sellitto C; Li L; Vaghefi E; Donaldson PJ; Lin RZ; White TW
Invest Ophthalmol Vis Sci; 2016 Jun; 57(7):3145-51. PubMed ID: 27304846
[TBL] [Abstract][Full Text] [Related]
15. Enhanced PI3K p110α signaling confers acquired lapatinib resistance that can be effectively reversed by a p110α-selective PI3K inhibitor.
Brady SW; Zhang J; Seok D; Wang H; Yu D
Mol Cancer Ther; 2014 Jan; 13(1):60-70. PubMed ID: 24249715
[TBL] [Abstract][Full Text] [Related]
16. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis.
Jia S; Liu Z; Zhang S; Liu P; Zhang L; Lee SH; Zhang J; Signoretti S; Loda M; Roberts TM; Zhao JJ
Nature; 2008 Aug; 454(7205):776-9. PubMed ID: 18594509
[TBL] [Abstract][Full Text] [Related]
17. Over-expression of the p110beta but not p110alpha isoform of PI 3-kinase inhibits motility in breast cancer cells.
Yip SC; El-Sibai M; Hill KM; Wu H; Fu Z; Condeelis JS; Backer JM
Cell Motil Cytoskeleton; 2004 Nov; 59(3):180-8. PubMed ID: 15468162
[TBL] [Abstract][Full Text] [Related]
18. Dominant Role of PI3K p110α over p110β in Insulin and β-Adrenergic Receptor Signalling.
Zhang B; Luk C; Valadares J; Aronis C; Foukas LC
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884613
[TBL] [Abstract][Full Text] [Related]
19. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC
Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanism of activation of class IA phosphoinositide 3-kinases (PI3Ks) by membrane-localized HRas.
Siempelkamp BD; Rathinaswamy MK; Jenkins ML; Burke JE
J Biol Chem; 2017 Jul; 292(29):12256-12266. PubMed ID: 28515318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
